Click here to proceed to the document
Servier and Vernalis plc are pleased to announce the achievement of two research milestones and one clinical milestone in their oncology drug discovery collaboration, triggering a total payment of €2 million to Vernalis.
More information on Vernalis and its pipeline ...
Company fact sheet
Explore the pipeline ...
T: 0118 938 0000 F: 0118 938 0001Contact informationMaps and directionsContact form
To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and email@example.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch